SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-070935
Filing Date
2023-12-18
Accepted
2023-12-18 07:00:29
Documents
14
Period of Report
2023-12-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20231218.htm   iXBRL 8-K 40513
2 EX-99.1 lxeo-ex99_1.htm EX-99.1 17433
3 GRAPHIC img46940271_0.jpg GRAPHIC 221501
  Complete submission text file 0000950170-23-070935.txt   467462

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lxeo-20231218_lab.xml EX-101.LAB 14010
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lxeo-20231218_pre.xml EX-101.PRE 10285
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lxeo-20231218.xsd EX-101.SCH 2466
8 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20231218_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

IRS No.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 231492222
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)